Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Urinary Tract Infection

Conditions

Urinary Tract Infection

Trial Timeline

Apr 1, 2013 → Dec 1, 2014

About Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)

Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate) is a approved stage product being developed by Astellas Pharma for Urinary Tract Infection. The current trial status is unknown. This product is registered under clinical trial identifier NCT02094703. Target conditions include Urinary Tract Infection.

What happened to similar drugs?

20 of 20 similar drugs in Urinary Tract Infection were approved

Approved (20) Terminated (1) Active (0)
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
SolifenacinAstellas PharmaApproved
Tamsulosin + SolifenacinAstellas PharmaApproved
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
solifenacin succinate + PlaceboAstellas PharmaApproved
solifenacinAstellas PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02094703ApprovedUNKNOWN

Competing Products

20 competing products in Urinary Tract Infection

See all competitors
ProductCompanyStageHype Score
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
Duloxetine + placeboEli LillyPhase 2
35
DuloxetineEli LillyPhase 2
35
Enfortumab vedotinAstellas PharmaPhase 1
21
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
43
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
35
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaPre-clinical
26
TamuslosinAstellas PharmaPhase 3
40
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
TamusulosinAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
40
Solifenacin succinate + PlaceboAstellas PharmaPhase 3
40